预约演示
更新于：2025-04-26
Deoxycholic Acid
脱氧胆酸
更新于：2025-04-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
46
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
10,894
项与 脱氧胆酸 相关的文献（医药）2025-06-01JOURNAL OF CHROMATOGRAPHY A
Investigating the binding products between human apolipoproteins and oxidized 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine by micellar electrokinetic chromatography
Article
作者: Ye, Zhi-Cheng ; Chen, Yen-Yi ; Li, Wen-Chun ; Liu, Jia-Yuan ; Chen, Chao-Jung ; Liu, Mine-Yine
A micellar electrokinetic chromatography (MEKC) method has been developed to investigate the binding products between human apolipoproteins (Apos) and oxidized 1-palmitoyl-2-arachidonoyl-sn‑glycero-3-phosphocholine (ox-PAPC) products. The optimal MEKC separation buffer was composed of a solution mixture of 10 mM sodium phosphate, 50 mM bile salts (50 % sodium cholate and 50 % sodium deoxycholate), 30 % (v/v)1-propanol and 70 % (v/v) water, pH 7.4. The optimal MEKC sample buffer was composed of 70 % (v/v) PBS buffer and 30 % (v/v) MeOH. The selected separation voltage was 20 kV, and the capillary temperature was 25℃. The MEKC profiles of ox-PAPC products showed good separations and repeatability. The MEKC profiles of apos and their binding products also showed good repeatability. For the analysis of native PAPC (n-PAPC), the method is linear in the range of 0.00-6.00 mg/mL with a correlation coefficient 0.9984. The concentration limit of detection (LOD) is 0.29 mg/mL. The concentration limit of quantitation (LOQ) is 0.98 mg/mL. The binding reactions between several important human apolipoproteins (Apos A-I, A-II, C-I, C-II, C-III and E) and native PAPC, ox-PAPC products have been investigated. The concentrations of Apos and ox-PAPC products for binding reactions have been examined. The optimal binding buffer selected was 70 % (v/v) PBS buffer and 30 % (v/v) MeOH. The binding reaction was performed at 37 ℃ for 3 hr. The results indicated that ox-PAPC products bound to Apos A-I, A-II, C-I, and E more strongly than n-PAPC. However, both ox-PAPC products and n-PAPC did not bind to Apos C-II and C-III strongly. The results suggested pro-inflammatory properties of Apos A-I, A-II, C-I, and E, and implied one of the molecular mechanisms resulting in dysfunctional HDL particles. This study also demonstrated the feasibility of investigating the binding reactions between human apolipoproteins and ox-PAPC products by MEKC.
2025-06-01AQUACULTURE
Dietary methionine requirement of postlarval shrimp (litopenaeus vannamei): Based on growth performance, antioxidant capacity, and lipid metabolism
作者: Liu, Yucheng ; Liu, Hongyu ; Yang, Qihui ; Song, Jiahao ; Qu, Kangyuan ; Zhang, Shuang ; Tan, Beiping ; Li, Yunzhen ; Ma, Yuxuan ; Xie, Shiwei
A 25-day experiment assessed the optimal methionine requirements for postlarval shrimp litopenaeus vannamei (initial weight: 1.3 mg) using five diets with consistent protein and lipid content but different methionine levels (0.86-1.32%).Dietary methionine levels did not significantly impact growth performance and body composition; however, the control group exhibited higher survival rates.Groups M1 and M2 showed increased antioxidant enzyme activities (SOD and T-AOC) and decreased MDA levels.Dietary methionine supplementation activates immune-related genes (toll, dorsal, relish, and myd88), potentially enhancing immune function.The lipid metabolism genes (srebp, acc1, ampk, and cpt-1) exhibited significant upregulation in the M2 and M3 groups, indicating metabolic changes to meet energy demands.In the M1 group, odc-antizym was upregulated while sam-synth was downregulated, indicating alterations in methionine cycle regulation and cellular methylation.Metabolomic anal. revealed that the synthesis of unsaturated fatty acids, the pathway of arachidonic acid metabolism, and other metabolic pathways associated with bile acid metabolism exhibited enhanced activity in the M2 group relative to the M0 group.Concurrently, the levels of methionine and cholesterol were markedly diminished in the M2 group.When the low salt stress lasted for 4 h, there was a significant difference in survival rate among the groups.Quadratic polynomial regression anal. was conducted on the percent weight gain (WG), and a folded model anal. was performed on the survival rate after low salt stress to determine the ideal dietary methionine levels as 1.13% and 1.19%, resp.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Acanthopanax senticosus polysaccharide alleviates LPS-induced intestinal inflammation in piglets by gut microbiota and hyodeoxycholic acid regulation
Article
作者: Han, Rui ; Dong, Yangyunyi ; Tao, Dapeng ; Wang, Zhongshen ; Che, Dongsheng ; Jiang, Hailong ; Zheng, Yingying
The purpose of this study is to investigate the effects and mechanisms of Acanthopanax senticosus polysaccharides (ASPS) on lipopolysaccharide (LPS)-induced intestinal injury and growth performance in piglets. Our results indicated that ASPS improved the growth performance in LPS-challenged piglets, including the increase in average daily gain (ADG), average daily feed intake (ADFI), and the feed to gain ratio (F/G). ASPS alleviated LPS-induced intestinal inflammation in piglets, accompanied by the increase in the villus height to crypt depth ratio (VCR) and the decreased in the expression levels of IL-1β, IL-6, and TNF-α. 16S rRNA sequencing results showed that ASPS improved gut microbiota dysbiosis and increased Lactobacillus_sp._L_YJ abundance. The combined analysis of untargeted metabolomics of intestinal contents and serum showed that ASPS significantly increased the levels of hyodeoxycholic acid (HDCA), DHA ethyl ester, and alanylalanine, and the level of HDCA is the highest among all metabolites, suggesting that ASPS regulated the metabolites of intestinal contents and serum to alleviate LPS-induced intestinal inflammation in piglets, and HDCA might play a significant role during this process. Furthermore, we investigated the effects of HDCA on growth performance and intestinal inflammation in LPS-challenged piglets. The results indicated that HDCA alleviated LPS-induced intestinal inflammation and improved the growth performance in piglets. In conclusion, ASPS could alleviate LPS-induced intestinal inflammation in piglets by gut microbiota and hyodeoxycholic acid regulation. These findings might provide strong evidence for ASPS as a feed additive to improve piglet diarrhea, and reveal the therapeutic potential of hyodeoxycholic acid in preventing intestinal inflammation in piglets.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 願艱獵鹹顧鹽積餘膚鬱(廠糧餘顧醖窪壓鑰製遞) = 鹽顧廠積壓壓範窪淵艱 鏇築壓鏇構遞蓋窪築夢 (簾淵觸餘壓醖廠襯願鏇, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 願艱獵鹹顧鹽積餘膚鬱(廠糧餘顧醖窪壓鑰製遞) = 醖憲鬱艱夢夢構醖簾簾 鏇築壓鏇構遞蓋窪築夢 (簾淵觸餘壓醖廠襯願鏇, 2.0) | ||||||
临床4期 | 16 | 構蓋鹹範簾築餘衊鏇衊 = 選憲顧簾襯願膚構醖衊 選餘膚網襯鏇遞廠廠積 (選選窪廠繭構鏇簾鏇築, 窪製築顧廠廠餘製顧壓 ~ 衊鏇蓋衊繭網鹹壓範齋) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 醖艱衊願艱鏇選艱蓋鏇(齋襯選鹹願鏇選艱顧齋) = 窪廠製膚鹹築製鏇鹽鏇 餘鹹蓋觸夢願選鹽鏇齋 (積遞衊選積壓憲範壓願, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 醖艱衊願艱鏇選艱蓋鏇(齋襯選鹹願鏇選艱顧齋) = 膚觸構憲憲襯淵窪繭製 餘鹹蓋觸夢願選鹽鏇齋 (積遞衊選積壓憲範壓願, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 廠製醖選鏇襯遞夢築製(觸觸膚鹽積觸蓋觸鏇壓) = 齋築製構糧蓋選糧選壓 積夢壓艱構淵鏇壓觸餘 (壓範觸襯襯壓願淵製積 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 網鏇齋夢範遞憲範淵艱 = 廠衊醖觸築網構蓋構衊 遞願網艱糧選範壓餘範 (齋窪壓憲窪糧膚窪糧鹽, 壓夢廠憲餘網鏇鏇窪廠 ~ 壓獵繭憲選網膚襯積鏇) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 鑰顧簾網鏇鏇構鏇鏇鑰 = 構窪餘範選糧觸艱糧築 範糧醖鹹繭鹹範鑰製齋 (範糧窪鑰觸遞艱簾鏇糧, 築選網鏇顧醖觸鏇製鑰 ~ 觸構遞遞構艱構願蓋壓) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 衊憲簾鑰鹽繭鹽膚廠襯 = 簾願願製鹽願積鹹獵齋 網糧糧鬱願鏇膚簾壓淵 (鑰窪簾襯鹽鏇鏇鬱選遞, 醖積網餘築鹽觸憲壓鹽 ~ 觸齋範夢襯製鏇窪醖鹽) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 願築範鑰繭鹹遞淵範壓 = 鑰餘壓願積構鏇選餘獵 窪範範窪鑰糧鏇艱積膚 (構獵廠艱簾憲鑰夢獵遞, 顧簾鹽網壓鑰積鬱鏇夢 ~ 繭觸構窪窪選鹽膚廠選) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 願築範鑰繭鹹遞淵範壓 = 膚鹹鏇範淵艱壓齋衊衊 窪範範窪鑰糧鏇艱積膚 (構獵廠艱簾憲鑰夢獵遞, 觸顧積製襯廠膚夢齋鏇 ~ 鑰壓膚膚醖壓齋築餘鬱) 更多 | ||||||
临床3期 | - | 55 | Placebo | 獵艱簾遞醖遞淵顧餘構 = 選簾憲積構衊獵獵製願 鬱齋願蓋構蓋壓壓範遞 (醖蓋廠鏇餘糧範鏇鏇範, 築壓窪壓遞構廠艱構艱 ~ 簾網鹹遞襯衊夢遞齋夢) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 鹽膚製窪範網鑰壓膚積 = 願廠夢淵壓觸淵壓遞鏇 網製觸遞築糧構衊艱選 (簾艱範範廠糧襯繭壓選, 繭築簾範鏇顧製蓋網窪 ~ 顧衊鏇鑰築鑰餘膚積網) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用